Transparency in Partnerships with Patients and Medical Institutions

Guidelines for Transparency

Guidelines for Transparency

The mission of an R&D-oriented pharmaceutical company is to contribute to the health of people and medical care around the world through continually researching and developing new drugs and steadily bringing these to market, under the objective of creating "patient-participated medical care.

In order to fulfill this mission, it is essential to collaborate with research organizations including medical institutions and universities in all stages from drug discovery to post-marketing information provision activities ensuring the proper use of pharmaceuticals.

With representatives of patient groups sitting on an increasing number of government committees and investigative commissions as governments and the medical community put greater emphasis on the "voice of the patient," patient groups have become important stakeholders in the mission to improve medical care.

At Sumitomo Dainippon Pharma, we believe that it is critical to raise awareness and increase understanding throughout society that activities designed to improve coordination between medical institutions and patient groups are undertaken in accordance with high ethical standards.

The Japan Pharmaceutical Manufacturers Association (JPMA) issued its Transparency Guideline for the Relation between Corporate Activities and Medical Institutions on January 19, 2011, and its Transparency Guideline for the Relation between Corporate Activities and Patients' Groups on March 14, 2012.

As a member of the JPMA, we established our own Guidelines for Transparency in Partnerships with Medical Institutions in October 2011 and Guidelines for Transparency in Partnerships with Patients' Groups in April 2012. In accordance with these guidelines, we publicly disclose information on our corporate website on such issues as payments that we make to medical institutions, medical professionals, and patient advocacy and support groups.

Fair Promotion Activities

In view of the JPMA Promotion Code for Prescription Drugs, Sumitomo Dainippon Pharma has formulated the DSP Promotion Code for Prescription Drugs to specify the standards of conduct that MRs have to comply with when promoting ethical drugs with the aim of engaging in fair promotion activities. Moreover, The Fair Trade Council of the Ethical Pharmaceutical Drugs Marketing Industry has specified the Fair Competition Code Concerning Restriction on Premium Offers in Ethical Drugs Marketing Industry regarding the provision of premiums to healthcare professionals. In light of the relevant legislation and these voluntary standards, Sumitomo Dainippon Pharma has formulated the DSP-GPP (Good Promotion Practice) with the objective of engaging in fair and transparent marketing activities.

In fiscal 2014, we provided monthly training for MRs that included the JPMA and its rules, transparency guidelines (for medical institutions, etc.), a Code of Practice understanding and promotion month, product explanation sessions, small sum premiums, research sessions and lectures, public servant ethics code, and in-house training sessions.